The main objective of the proposal is to develop a new target-specific delivery system for the treatment of malignant glioma. For that purpose we have cloned a new fusion gene "Cave-in" which contains intracellular and membrane-spanning domains of scavenger receptor legated to avid in which will form the extra cellular domain of the fusion protein. Cave-in will be transfixed to target tissue with local gene therapy via catheter delivery or during surgical operation with adenovirus or pseudotyped retrovirus technology. Targeted treatment is achieved by binding of biotinylated compounds to Cave-in, which will be only expressed in the transfixed tissue.
Funding SchemeCSC - Cost-sharing contracts
W1T 6AR London
W1N 8AA London